{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:49:22Z","timestamp":1794649762836,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30 AI-28697"],"award-info":[{"award-number":["5P30 AI-28697"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA-16042"],"award-info":[{"award-number":["P30 CA-16042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T30DT0963"],"award-info":[{"award-number":["T30DT0963"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["1lK2BX006194-01"],"award-info":[{"award-number":["1lK2BX006194-01"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011075","name":"University of California Los Angeles David Geffen School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007186","name":"Jonsson Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.xcrm.2024.101479","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T10:41:29Z","timestamp":1711017689000},"page":"101479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-7858","authenticated-orcid":false,"given":"Raymond J.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Salehi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Dumitras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Crosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara E.","family":"Yean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Abascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiLing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostyantyn","family":"Krysan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Dubinett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101479_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101479_bib2","first-page":"e18","article-title":"Pembrolizumab plus Chemotherapy in Lung Cancer","volume":"379","author":"Gandhi","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101479_bib3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients With Advanced NonSmall-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101479_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101479_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101479_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2021.02.005","article-title":"Post-progression outcomes of NSCLC patients with PD-L1 expression >\/= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study","volume":"148","author":"Cortellini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101479_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103538","article-title":"Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?","volume":"169","author":"Insa","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2024.101479_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2023.02.002","article-title":"Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer","volume":"178","author":"Auclin","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2024.101479_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminoncol.2017.01.001","article-title":"Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials","volume":"44","author":"Kazandjian","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101479_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101479_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101479_bib12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101479_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2024.101479_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101479_bib15","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","article-title":"LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T\u00a0cell tumor-infiltration impairing anti-PD1 therapy","volume":"10","author":"Pascual-Garc\u00eda","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101479_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib17","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101479_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2024.101479_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abk1692","article-title":"Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy","volume":"7","author":"Hoch","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2024.101479_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T\u00a0cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101479_bib21","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101479_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic Cell-Based Cancer Vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101479_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/1078-0432.CCR-20-0473","article-title":"Intratumoral Immunotherapy: From Trial Design to Clinical Practice","volume":"27","author":"Champiat","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib24","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1158\/1078-0432.CCR-03-0380","article-title":"Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity","volume":"10","author":"Yang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/10430340050016157","article-title":"Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication","volume":"11","author":"Miller","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2024.101479_bib26","first-page":"2062","article-title":"T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy","volume":"61","author":"Kirk","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib27","article-title":"CCL21-DC in\u00a0situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity","volume":"11","author":"Salehi-Rad","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101479_bib28","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00262-020-02837-9","article-title":"Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden","volume":"70","author":"Salehi-Rad","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2024.101479_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2024.101479_bib30","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib31","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2004-08-2992","article-title":"Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells","volume":"105","author":"Muehlinghaus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101479_bib32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101479_bib33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib34","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-20-3564","article-title":"Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-2-22","article-title":"SLC\/CCL21-mediated anti-tumor responses require IFNgamma, MIG\/CXCL9 and IP-10\/CXCL10","volume":"2","author":"Sharma","year":"2003","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2024.101479_bib36","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101479_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T\u00a0cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101479_bib38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","article-title":"cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1","volume":"10","author":"Ferris","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib39","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/0008-5472.CAN-15-1122","article-title":"STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s40425-019-0797-4","article-title":"The density and spatial tissue distribution of CD8(+) and CD163(+) immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors","volume":"7","author":"Massi","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101479_bib41","article-title":"Distinct phenotypic states and spatial distribution of CD8(+) T\u00a0cell clonotypes in human brain metastases","volume":"3","author":"Sudmeier","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2024.101479_bib42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8\u00a0T Cell-Fate Decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101479_bib43","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T\u00a0cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101479_bib44","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s43018-020-00140-1","article-title":"Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44","volume":"1","author":"Cummings","year":"2020","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xcrm.2024.101479_bib45","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101479_bib46","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","article-title":"MHC-I Genotype Restricts the Oncogenic Mutational Landscape","volume":"171","author":"Marty","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101479_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccm.2019.10.003","article-title":"The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment","volume":"41","author":"Salehi-Rad","year":"2020","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.xcrm.2024.101479_bib48","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","article-title":"CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond","volume":"11","author":"Karin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101479_bib49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2016.172","article-title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer","volume":"115","author":"Bronger","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101479_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101479_bib51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101479_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.187.1.129","article-title":"Differential expression of chemokine receptors and chemotactic responsiveness of type 1\u00a0T helper cells (Th1s) and Th2s","volume":"187","author":"Bonecchi","year":"1998","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101479_bib53","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41590-022-01324-w","article-title":"Mechanisms of CD40-dependent cDC1 licensing beyond costimulation","volume":"23","author":"Wu","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101479_bib54","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1158\/0008-5472.CAN-19-0153","article-title":"The immune contexture associates with the genomic landscape in lung adenomatous premalignancy","volume":"79","author":"Krysan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib55","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.18632\/oncotarget.3205","article-title":"Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration","volume":"6","author":"Zumwalt","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2024.101479_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6509","article-title":"CXCL9 and CXCL10 bring the heat to tumors","volume":"7","author":"Reschke","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2024.101479_bib57","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101479_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101479_bib59","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022655118","article-title":"Immune evasion in HPV(-) head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss","volume":"118","author":"William","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101479_bib60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101479_bib61","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101479_bib62","doi-asserted-by":"crossref","first-page":"30219","DOI":"10.1074\/jbc.M403595200","article-title":"Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function","volume":"279","author":"Colvin","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101479_bib63","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/s41467-022-33569-2","article-title":"Location bias contributes to functionally selective responses of biased CXCR3 agonists","volume":"13","author":"Eiger","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101479_bib64","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13059-019-1874-1","article-title":"Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression","volume":"20","author":"Hafemeister","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2024.101479_bib65","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0192623315587593","article-title":"Introduction of Zinc-salt Fixation for Effective Detection of Immune Cell-related Markers by Immunohistochemistry","volume":"43","author":"Mori","year":"2015","journal-title":"Toxicol. Pathol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124001253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124001253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T23:58:28Z","timestamp":1714348708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124001253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2666379124001253"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101479","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101479"}}